Candida glabrata is unusual with respect to its resistance to cationic antifungal proteins.
Naturally occurring salivary antifungal proteins have been of major interest, due to their potential to provide the basis for peptide antimycotics effective in combating fungal infections in the oral cavity or elsewhere. We tested the fungistatic activity of a number of cationic antifungal proteins, with major emphasis on histatin 5, a basic protein secreted by the human parotid and submandibular glands. Histatin 5 inhibited the growth of Candida albicans and that of other medically important Candida species, such as C. kefyr, C. krusei, and C. parapsilosis, with IC50 values in the range of 10-20 microg/ml. Two Cryptococcus neoformans strains were also sensitive (IC50 5.2 and 5.6 microg/ml). On the other hand, three C. glabrata strains (ATCC 90030, 2001 and 64677) were entirely insensitive to histatin 5 (IC50>225 microg/ml). Four genetically very similar species to C. glabrata, Candida castelli (CBS 4332), Saccharomyces cerevisiae (S288C, BY4741 and CBS 1171), Kluyveromyces delphensis (CBS 2170) and Kluyveromyces bacillisporus (CBS 7720) were all sensitive to histatin 5 (IC50 2.6-64.6 microg/ml). C. glabrata was also insensitive to other members of the histatin family; histatin 1, 3 and P-113 (IC50 values in all cases >225 microg/ml). In addition, two entirely different cationic antifungal proteins originating from frog skin, PGLa and magainin 2, also showed a strong reduced activity toward this fungus. Besides the well-described inherent resistance of C. glabrata to azole-derived antifungal agents, our studies indicate that this species is also able to withstand the otherwise detrimental activities of cationic antifungal proteins.
Helmerhorst
Eva J
EJ
Department of Periodontology and Oral Biology, Goldman School of Dental Medicine, Boston University, 700 Albany Street, Boston, MA 02118, USA. helmer@bu.edu
Venuleo
Caterina
C
Beri
Anuradha
A
Oppenheim
Frank G
FG
D000935:Antifungal Agents / Q000494:pharmacology*; D023181:Antimicrobial Cationic Peptides / Q000494:pharmacology*; D041221:Candida glabrata / Q000187:drug effects* / Q000254:growth & development; D025141:Drug Resistance, Fungal; D006801:Humans; D020128:Inhibitory Concentration 50; D054806:Magainins; D008826:Microbial Sensitivity Tests; D011506:Proteins / Q000494:pharmacology*; D012471:Salivary Proteins and Peptides / Q000494:pharmacology*; D029867:Xenopus Proteins / Q000494:pharmacology*; D000099053:Histidine-Rich Glycoprotein
D000935:Antifungal Agents; D023181:Antimicrobial Cationic Peptides; D054806:Magainins; D011506:Proteins; D012471:Salivary Proteins and Peptides; D029867:Xenopus Proteins; D000099053:Histidine-Rich Glycoprotein; C053301:magainin 2 peptide, Xenopus